Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype
- PMID: 20185345
- DOI: 10.1016/j.bcmd.2010.02.005
Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype
Abstract
Asymmetric dimethylarginine (ADMA) is associated with pulmonary hypertension (PHT) in sickle cell disease (SCD). We studied the relationship of ADMA to other SCD-related complications. Plasma ADMA and associated parameters were determined in 52 HbSS/HbSbeta(0)-thalassemia and 24 HbSC/HbSbeta(+)-thalassemia patients. As expected ADMA levels were higher in HbSS/HbSbeta(0)-thalassemia patients with PHT (p=0.018), but also in those with other hemolysis-associated complications such as leg ulcers (p=0.012), cholelithiasis (p=0.008) and priapism (p=0.02) compared with counterparts without these complications. ADMA levels did not differ between patients with and without other disease related complications such as retinopathy and avascular osteonecrosis. Higher ADMA concentrations therefore seem to be associated to the hemolytic phenotype of SCD.
Comment in
-
Massive quantities of asymmetric dimethylarginine (ADMA) are incorporated in red blood cell proteins and may be released by proteolysis following hemolytic stress.Blood Cells Mol Dis. 2010 Jun 15;45(1):40. doi: 10.1016/j.bcmd.2010.03.004. Epub 2010 Apr 8. Blood Cells Mol Dis. 2010. PMID: 20381387 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials